Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dako, a provider of cancer diagnostic solutions, has signed an agreement with Genentech, a biotechnology company, for a drug-companion diagnostic co-development program for a targeted cancer therapy.
Subscribe to our email newsletter
Under the terms of the agreement Dako and Genentech will collaborate on developing a new cancer diagnostic test as a potential companion product for a specific Genentech investigational therapeutic.
The collaboration involves the use of Dako’s experience in developing cancer diagnostic tests to identify cancer patients who may receive greater benefits from a certain therapy.
The collaboration is said to be in line with Dako’s ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop the offering of its Pharmacodiagnostic assays.
Patrik Dahlen, CEO and president of Dako, said: “We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies.
“We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently managing healthcare costs.”